BioDelivery Sciences International and Arcion Therapeutics have signed a worldwide licensing deal for the development and commercialization of topical clonidine gel (previously ARC4558) to treat painful diabetic neuropathy (PDN) and other ...
Tags: BioDelivery, Arcion Therapeutics, topical clonidine gel development
American pharmaceutical company BioDelivery Sciences (BDSI) has completed the safety and tolerability trial of BEMA Buprenorphine/Naloxone (BNX), which is indicated for the treatment of opioid dependent patients. BDSI claims that BNX, ...
Tags: BioDelivery Sciences, BEMA Buprenorphine, opioid dependent patients
BioDelivery Sciences International, a developer of drug delivery technologies, and Endo Health Solutions have started enrolling patients for its Phase 3 clinical program of BEMA Buprenorphine, designed as a treatment for moderate to severe ...
Tags: BioDelivery Sciences International, Endo Health Solutions
BioDelivery Sciences International (BDSI) announced that the USPTO has granted BDSI's patent which extends the patent protection for BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven ...